Dupilumab - Oesophagitis (inducing remission)

You are here : Home > Formulary Search > Dupilumab - Oesophagitis (inducing remission)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative

Formulations :

No records returned.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NFD2

Restrictions / Comments :

Important

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Dupilumab

Indication :

Oesophagitis (inducing remission)

Group Name :

Keywords :

Eosinophilic oesophagitis

Brand Names Include :

Dupixent

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Dupilumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Oesophagitis (inducing remission).

Budesonide

Committee Recommendations (1)

09 Oct 24 - Not Set

This drug has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.